Taking a look at valuation rankings for MEI Pharma, Inc. (NasdaqCM:MEIP), we see that the stock has a Value Composite score of 94. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 91.

Investors might be shifting their focus trying to gauge the next big stock market move. Some may be contemplating recent action, and it remains to be seen if the momentum will push the market higher, or if a pullback is in the cards. Investors may have to make a decision whether to take a conservative stance, or put the pedal to the metal. Investors may also be closely tracking the underperformers and over performers, especially in the hot sectors. Studying specific sectors may provide some insight on which stocks are primed for a breakout. Comparing stocks within the same industry or sector may also help discover which ones are more likely to outperform over the next few quarters.

In taking a look at some other notable technicals, MEI Pharma, Inc. (NasdaqCM:MEIP)’s ROIC is -5.652876. The ROIC 5 year average is -5.495913 and the ROIC Quality ratio is -1.008520. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

The Q.i. Value of MEI Pharma, Inc. (NasdaqCM:MEIP) is 79.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of MEI Pharma, Inc. (NasdaqCM:MEIP) is -0.062568.

Quant Scores

MEI Pharma, Inc. (NasdaqCM:MEIP) currently has a Montier C-score of 0.00000. This indicator was developed by James Montier in an attempt to identify firms that were cooking the books in order to appear better on paper. The score ranges from zero to six where a 0 would indicate no evidence of book cooking, and a 6 would indicate a high likelihood. A C-score of -1 would indicate that there is not enough information available to calculate the score. Montier used six inputs in the calculation. These inputs included a growing difference between net income and cash flow from operations, increasing receivable days, growing day’s sales of inventory, increasing other current assets, decrease in depreciation relative to gross property plant and equipment, and high total asset growth.

MEI Pharma, Inc. (NasdaqCM:MEIP) has an M-score Beneish of -999.000000. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

At the time of writing, MEI Pharma, Inc. (NasdaqCM:MEIP) has a Piotroski F-Score of 1. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

MEI Pharma, Inc. (NasdaqCM:MEIP) has a current MF Rank of 17091. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

As the next earnings season comes into focus, investors will be keeping watch on the performance of companies that they own. A company that continually exceeds earnings projections is most likely on the right track. On the other end of the spectrum, a company that frequently misses earnings projections might provide some insight to the fact that something isn’t right. Although it is important to keep track of earnings estimates and results, it shouldn’t be the only thing that the investor is looking at regarding the stock. Just because a company misses or beats expectations for one quarter may not mean anything super special. Tracking performance over a longer period of time can help paint the bigger picture of what is going on with the company. Sharp investors often have the ability to look deeper into the numbers to see the actual causes of an earnings hit or miss. Of course estimates are just that, estimates, and some analysts may be more accurate than others.

Shareholder YieldWe also note that MEI Pharma, Inc. (NasdaqCM:MEIP) has a Shareholder Yield of -0.007614 and a Shareholder Yield (Mebane Faber) of -0.91249. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

MF RankMEI Pharma, Inc. (NasdaqCM:MEIP) has a current MF Rank of 17091. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

PIWe can now take aquick look at some historical stock price index data. MEI Pharma, Inc. (NasdaqCM:MEIP) presently has a 10 month price index of 1.49180. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period.

A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.32847, the 24 month is 1.85714, and the 36 month is 2.17964. Narrowing in a bit closer, the 5 month price index is 1.68519, the 3 month is 1.49180, and the 1 month is currently 0.82727.

Market slides can be troublesome for investors. When markets are moving lower, investors may become extra nervous about certain holdings. With the stock market reaching heightened levels, investors may not be putting too much though into the specific portfolio holdings. This can all change if there is a sudden downturn. Investors who have spent the hours researching their stock picks may be more confident when the tides inevitably turn. Putting in the time to regularly review stock holdings may assist the investor when certain adjustments need to be made. Focusing on developing and maintaining a solid plan may end up being a useful tool when obstacles eventually pop up down the line.